Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

/pdf/effective-use-of-nanocarriers-as-drug-delivery-systems-for-3xi38zjbzk.pdf

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.

The early detection of cancer can significantly reduce cancer mortality and saves lives. Thus, a great deal of effort has been devoted to the exploration of new technologies to detect early signs of the disease. Cancer biomarkers cover a broad range of biochemical entities, such as nucleic acids, proteins, sugars, small metabolites, and cytogenetic and cytokinetic parameters, as well as entire tumour cells found in the body fluid. They can be used for risk assessment, diagnosis, prognosis, and for the prediction of treatment efficacy and toxicity and recurrence. In this review, we provide an overview of recent advances in cancer biomarker detection. Several representative examples using different approaches for each biomarker have been reviewed, and all these cases demonstrate that the multidisciplinary technology-based cancer diagnostics are becoming an increasingly relevant alternative to traditional techniques. In addition, we also discuss the unsolved problems and future challenges in the evaluation of cancer biomarkers. Clearly, solving these hurdles requires great effort and collaboration from different communities of chemists, physicists, biologists, clinicians, material-scientists, and engineering and technical researchers. A successful outcome will result in the realization of point-of-care diagnosis and individualized treatment of cancers by non-invasive and convenient tests in the future.

Cancer biomarker detection: recent achievements and challenges

Biochemical Pathways Meggie Hakim,† Yoav Y. Broza,† Orna Barash,† Nir Peled,‡ Michael Phillips, Anton Amann, and Hossam Haick*,† †The Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, TechnionIsrael Institute of Technology, Haifa 32000, Israel ‡The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel-Aviv University, Tel-Aviv 52621, Israel Menssana Research, Inc., Fort Lee, New Jersey 07024, United States Breath Research Institute, Austrian Academy of Sciences, 6850 Dornbirn, Austria University-Clinic for Anesthesia, Innsbruck Medical University, 6020 Innsbruck, Austria

Volatile organic compounds of lung cancer and possible biochemical pathways.

Tumour growth is accompanied by gene and/or protein changes that may lead to peroxidation of the cell membrane species and, hence, to the emission of volatile organic compounds (VOCs). In this study, we investigated the ability of a nanosensor array to discriminate between breath VOCs that characterise healthy states and the most widespread cancer states in the developed world: lung, breast, colorectal, and prostate cancers. Exhaled alveolar breath was collected from 177 volunteers aged 20–75 years (patients with lung, colon, breast, and prostate cancers and healthy controls). Breath from cancerous subjects was collected before any treatment. The healthy population was healthy according to subjective patient's data. The breath of volunteers was examined by a tailor-made array of cross-reactive nanosensors based on organically functionalised gold nanoparticles and gas chromatography linked to the mass spectrometry technique (GC-MS). The results showed that the nanosensor array could differentiate between ‘healthy’ and ‘cancerous’ breath, and, furthermore, between the breath of patients having different cancer types. Moreover, the nanosensor array could distinguish between the breath patterns of different cancers in the same statistical analysis, irrespective of age, gender, lifestyle, and other confounding factors. The GC-MS results showed that each cancer could have a unique pattern of VOCs, when compared with healthy states, but not when compared with other cancer types. The reported results could lead to the development of an inexpensive, easy-to-use, portable, non-invasive tool that overcomes many of the deficiencies associated with the currently available diagnostic methods for cancer.

/pdf/detection-of-lung-breast-colorectal-and-prostate-cancers-48vr41fxc6.pdf

Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors

Nanoparticle technology plays a key role in providing opportunities and possibilities for the development of new generation of sensing tools. The targeted sensing of selective biomolecules using functionalized gold nanoparticles (Au NPs) has become a major research thrust in the last decade. Au NP-based sensors are expected to change the very foundations of sensing and detecting biomolecules. In this review, we will discuss the use of surface functionalized Au NPs for smart sensor fabrication leading to detection of specific biomolecules and heavy metal ions.

A Review on Functionalized Gold Nanoparticles for Biosensing Applications

Conventional diagnostic methods for lung cancer 1,2 are unsuitable for widespread screening 2,3 because they are expensive and occasionally miss tumours. Gas chromatography/mass spectrometry studies have shown that several volatile organic compounds, which normally appear at levels of 1–20 ppb in healthy human breath, are elevated to levels between 10 and 100 ppb in lung cancer patients 4–6 . Here we show that an array of sensors based on gold nanoparticles can rapidly distinguish the breath of lung cancer patients from the breath of healthy individuals in an atmosphere of high humidity. In combination with solidphase microextraction 7 , gas chromatography/mass spectrometry was used to identify 42 volatile organic compounds that represent lung cancer biomarkers. Four of these were used to train and optimize the sensors, demonstrating good agreement between patient and simulated breath samples. Our results show that sensors based on gold nanoparticles could form the basis of an inexpensive and non-invasive diagnostic tool for lung cancer. Lung cancer accounts for 28% of cancer-related deaths.

Nisrean Shehada

Papers

Diagnosing lung cancer in exhaled breath using gold nanoparticles.